undergoing

Candoxatril (UK 79300) is an orally active neutral peptide endonuclease (NEP, EC 3.4.24.11) inhibitor that improves exercise capacity in patients with chronic heart failure undergoing angiotensin-converting enzyme inhibition.

Prasugrel (CS-747) is a piperazine derivative and PLATELET AGGREGATION INHIBITOR that is used to prevent THROMBOSIS in patients with ACUTE CORONARY SYNDROME; UNSTABLE ANGINA and MYOCARDIAL INFARCTION, as well as in those undergoing PERCUTANEOUS CORONARY INTERVENTIONS.

Inosine pranobex (Delimmun) has a number of immunomodulatory effects, including inducing T-lymphocyte differentiation, augmenting macrophage and NK cell functions, and stimulating IL-2 production. Through these effects and others, isoprinosine shows antiviral activity and has applications against subacute sclerosing panencephalitis. It also restores depressed immune responses in Y patients after irradiation and reduces the incidence of infection in leukemia patients undergoing chemotherapy. It is most commonly used to treat the rare measles complication subacute sclerosing panencephalitis in conjunction with intrathecal interferon therapy.

2-Hexylthiophene, a weakly basic heteroaromatic compound, can enhance the molar absorption coefficient of ruthenium sensitizers by undergoing modification.

(R)-3-Hydroxy Midostaurin is a potent inhibitor of kinases,is a major metabolite of midostaurin undergoing by the hepatic CYP3A4 enzyme,has the potential for acute myeloid leukemia (AML).

AZ-Dyrk1B-33 (3-(2-Methyl-4-pyrimidinyl)-1-(phenylmethyl)-1H-pyrrolo[2,3-c]pyridine) is a potent and selective Dyrk1B kinase inhibitor with an IC50 of 7 nM.

Oxamflatin (Metacept-3) is a selective histone deacetylase (HDAC) inhibitor characterized by high potency (IC50 = 15.7 nM) and the presence of an alkyne group capable of undergoing azide-alkyne cycloaddition reactions (CuAAc).

D-Citrulline (H-D-Cit-OH), a stereoisomer of L-citrulline, effectively reduces cardiac contractile dysfunction caused by polymorphonuclear leukocyte (PMN) in isolated perfused rat hearts undergoing ischemia reperfusion. This protective effect is mediated through a non-NO-mediated mechanism.

Protoporphyrin IX disodium, as a radiation sensitizer, enhances the production of ROS and induces DNA damage even under hypoxic conditions. It also acts as a photosensitizer, undergoing direct degradation through photobleaching upon light exposure. This compound accumulates in rat tumor cells following administration of 5-aminolevulinic acid (5-ALA). When activated with a peak wavelength of 405 nm, Protoporphyrin IX disodium selectively improves basal cell carcinoma. It shows promise in pharmacological research of sonodynamic and photodynamic therapy for cancers such as bladder cancer and nodular basal cell carcinoma.

22-Hydroxy Mifepristone (RU 42698) is an orally active hydroxylated alcohol metabolite that exhibits both anti-progestational and anti-glucocorticoid activities. This compound contains an alkyne group and is capable of undergoing copper-catalyzed azide-alkyne cycloaddition (CuAAC) with azide-containing molecules. Furthermore, 22-Hydroxy Mifepristone demonstrates a relative binding affinity of 48% to the human glucocorticoid receptor.

Batanopride (originally named BMY-25801) is a 5-HT3 receptor antagonist that has been utilized in research to address vomiting in cancer patients undergoing chemotherapy.

Histamine glutarimide is currently undergoing investigative research for its therapeutic efficacy in patients with bronchial asthma.

Imarikiren (also known as TAK-272) is a potent, highly selective, orally bioavailable direct renin inhibitor primarily used for treating diabetic nephropathy. In hPRA assays, TAK-272 exhibits strong inhibitory activity against human renin (IC50 = 2.1 nM) and demonstrates excellent selectivity over other aspartic proteases such as pepsin (IC50 > 10 μM) and cathepsin D (IC50 > 10 μM). In rats, TAK-272 shows significantly improved pharmacokinetic properties (F = 25.2%) and, upon oral administration (3 and 10 mg kg), exhibits a dose-dependent, potent, and sustained antihypertensive effect. Currently, TAK-272 HCl is undergoing human clinical trials.

Pegulicianine is an imaging agent utilized to detect residual cancer cells in the tumor bed of female patients undergoing breast-conserving surgery (BCS).

TAS2940 is an irreversible pan-ERBB inhibitor with enhanced brain penetration, utilized for treating lung cancer brain metastases and glioblastomas with HER2 EGFR exon 20 insertions and EGFR abnormalities. In intracranial xenograft models of HER2 EGFR cancers, TAS2940 has demonstrated efficacy in improving survival rates in mice. Currently, TAS2940 is undergoing Phase I clinical trials to establish the maximum tolerated dose for solid tumors.

RG7304 (also known as R7304 or CK-127) is a MEK inhibitor currently undergoing clinical trials.

TA 078 is an antidiabetic compound that effectively suppresses the rise in blood glucose levels when administered orally to mice undergoing glucose load.

CDK4 6-IN-23 (Compound 42) is a potent and selective inhibitor of CDK4 6, displaying an IC50 of 11 nM for CDK6. This compound significantly activates immune cells and enhances IL-3 production. In mice undergoing 5-FU chemotherapy, CDK4 6-IN-23 demonstrates dual bone marrow protection and immunomodulatory effects.

TMC647055 Choline Hydroxide Salt is a novel and potent non-nucleoside inhibitor of the HCV NS5B polymerase which potentially for the treatment of HCV infection. It has nanomolar cellular potency (EC(50) of 82 nM) with minimal associated cell toxicity (CC(

C17 Ceramide is a synthetic ceramide that contains a non-natural C17:0 fatty acid acylated to sphingosine. It has been used as a marker of arylsulfatase A and sphingolipid activator B activity in patients undergoing enzyme replacement therapy for the genetic disease metachromatic leukodystrophy.

Tariquidar is a P-glycoprotein inhibitor undergoing research as an adjuvant against multidrug resistance in cancer. Tariquidar non-competitively binds to the p-glycoprotein transporter, thereby inhibiting transmembrane transport of anticancer drugs.

Etanterol is a phenethanolamine derivative and a β2 adrenoceptor agonist that was undergoing phase II trials in Italy as a bronchodilator with Valeas.

Ciprostene (free base) is a synthetic, chemically stable analog of prostacyclin (PGI2). In animal models, administration of ciprostene resulted in dose-dependent hypotension, tachycardia, and inhibition of ex vivo ADP-induced platelet aggregation. Ciprostene was evaluated in clinical trials in patients with peripheral vascular disease. It was found to reduce restenosis in patients with coronary artery disease undergoing therapeutic percutaneous transluminal coronary angioplasty.

ABI-231 is a potent, orally bioavailable tubulin inhibitor that interacts with the colchicine binding site and is currently undergoing clinical trials for prostate cancer. ABI-231, has an average IC50 = 5.2 nM against panels of melanoma and prostate cancer cell lines, is orally bioavailable, and strongly suppress melanoma tumors in vivo. ABI-231 holds great promise as a new generation of orally available tubulin inhibitor.